<unk>  is a multikinase inhibitor that is FDA approved for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC)..   Common adverse reactions include diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.
Cabozantinib
Encorafenib
Enasidenib
Baricitinib
Regorafenib
Ivosidenib
Gilteritinib
Brigatinib